Timothy Eugene Sullivan Apellis Pharmaceuticals, Inc. (APLS) insider trading activity

Timothy Eugene Sullivan is Chief Financial Officer of Apellis Pharmaceuticals, Inc.. Currently has a direct ownership of 93,901 shares of APLS, which is worth approximately $1.91 Million. The most recent transaction as insider was on Jan 22, 2026, when has been sold 10,287 shares (Common Stock) at a price of $21.77 per share, resulting in proceeds of $223,947. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 93.9K

15.36% 3M change

27.02% 12M change

Total Value Held $1.91 Million

Timothy Eugene Sullivan Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Jan 22 2026	SELL Open market or private sale	$223,947 $21.77 p/Share	10,287 Reduced 9.87%	93,901 Common Stock
Jan 20 2026	SELL Open market or private sale	$57,232 $19.79 p/Share	2,892 Reduced 2.7%	104,188 Common Stock
Jan 13 2026	SELL Open market or private sale	$85,564 $22.19 p/Share	3,856 Reduced 3.48%	107,080 Common Stock
Oct 21 2025	SELL Open market or private sale	$280,300 $28.03 p/Share	10,000 Reduced 8.27%	110,936 Common Stock
Oct 21 2025	BUY Exercise of conversion of derivative security	$100,300 $10.03 p/Share	10,000 Added 7.64%	120,936 Common Stock
Sep 08 2025	SELL Open market or private sale	$911,829 $27.86 p/Share	32,729 Reduced 22.78%	110,936 Common Stock
Sep 08 2025	BUY Exercise of conversion of derivative security	$150,450 $10.03 p/Share	15,000 Added 9.45%	143,665 Common Stock

Jan 29 2025	SELL Open market or private sale	$16,117 $29.52 p/Share	546 Reduced 0.42%	128,665 Common Stock
Jan 22 2025	SELL Open market or private sale	$93,967 $30.43 p/Share	3,088 Reduced 2.33%	129,211 Common Stock
Jan 21 2025	BUY Grant, award, or other acquisition	-	45,929 Added 25.77%	132,299 Common Stock
Jan 17 2025	SELL Open market or private sale	$51,830 $29.96 p/Share	1,730 Reduced 1.96%	86,370 Common Stock
Jan 13 2025	SELL Open market or private sale	$62,279 $28.7 p/Share	2,170 Reduced 2.4%	88,100 Common Stock
Dec 31 2024	BUY Exercise of conversion of derivative security	$159,782 $14.4 p/Share	11,096 Added 10.95%	90,270 Common Stock
Apr 18 2024	SELL Bona fide gift	-	14,164 Reduced 15.17%	79,174 Common Stock
Apr 01 2024	SELL Open market or private sale	$234,640 $58.66 p/Share	4,000 Reduced 4.11%	93,338 Common Stock
Apr 01 2024	BUY Exercise of conversion of derivative security	$40,120 $10.03 p/Share	4,000 Added 3.95%	97,338 Common Stock
Mar 01 2024	SELL Open market or private sale	$380,460 $63.41 p/Share	6,000 Reduced 6.04%	93,338 Common Stock
Mar 01 2024	BUY Exercise of conversion of derivative security	$60,179 $10.03 p/Share	6,000 Added 5.7%	99,338 Common Stock
Feb 12 2024	SELL Open market or private sale	$96,978 $67.77 p/Share	1,431 Reduced 1.51%	93,338 Common Stock
Jan 29 2024	SELL Open market or private sale	$58,110 $64.14 p/Share	906 Reduced 0.95%	94,769 Common Stock
Jan 22 2024	SELL Open market or private sale	$230,815 $65.0 p/Share	3,551 Reduced 3.58%	95,675 Common Stock
Jan 16 2024	SELL Open market or private sale	$149,320 $66.81 p/Share	2,235 Reduced 2.2%	99,226 Common Stock
Jan 16 2024	BUY Grant, award, or other acquisition	-	23,748 Added 18.97%	101,461 Common Stock
Nov 30 2023	SELL Open market or private sale	$775,292 $54.76 p/Share	14,158 Reduced 15.41%	77,713 Common Stock
Nov 30 2023	BUY Exercise of conversion of derivative security	$142,004 $10.03 p/Share	14,158 Added 13.35%	91,871 Common Stock

TES

Timothy Eugene Sullivan

Chief Financial Officer

Waltham, MA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells APLS shares.

Notify only if

Value

Insider Trading

Get notified when an Apellis Pharmaceuticals, Inc. insider buys or sells APLS shares.

Notify only if

Operation

Value

Type

News

Receive news related to Apellis Pharmaceuticals, Inc.

Track Activities on APLS

Account